Primary and key secondary outcomes at 24 weeks (ITT)
| Active conventional therapy (ACT) | Certolizumab +MTX | Abatacept +MTX | Tocilizumab +MTX | |
|---|---|---|---|---|
| No of pts (ITT) | 200 | 203 | 204 | 188§ |
| Crude remission and response rates | ||||
| CDAI remission | 42.0% | 47.8% | 52.5% | 41.0% |
| ACR/EULAR Boolean remission | 34.0% | 38.4% | 37.3% | 31.4% |
| DAS28 remission | 63.5% | 68.5% | 69.6% | 63.3% |
| SDAI remission | 41.5% | 49.8% | 51.5% | 42.6% |
| EULAR good response | 71.5% | 76.9% | 79.9% | 71.3% |
| Difference (95% CI) in rates with Arm 1 as reference (adjusted) | ||||
| CDAI remission | Ref | 4% (-5 to 13%) | 9% (0.1 to 19%) | -1% (-10 to 9%) |
| ACR/EULAR Boolean remission | Ref | 4% (-6 to 13%) | 5% (-5 to 14%) | -4% (-13 to 6%) |
| DAS28 remission | Ref | 3% (-6 to 11%) | 5% (-4 to 13%) | -1% (-10 to 8%) |
| SDAI remission | Ref | 6% (-3 to 18%) | 9% (-0.3 to 18%) | 1% (-8 to 11%) |
| EULAR good response | Ref | 4% (-4 to 14%) | 8% (-2 to 18%) | 0.4% (-10 to 11%) |
§17 patients allocated to Tocilizumab did not receive it due to its unavailability and were excluded from ITT.